Key Highlights

  • Cash, cash equivalents and marketable securities totaled USD 798.4 million at September 30, 2026, which management believes funds operating expenses and Capital needs into 2030, an estimate that may prove wrong.
  • The net loss for the third quarter was USD 21.0 million, or USD 0.50 a share, versus USD 20.1 million a year earlier, as higher interest income of USD 5.1 million offset a rise in expenses.
  • General and administrative expense jumped to USD 12.7 million from USD 2.3 million, while Research and Development expense fell to USD 16.1 million from USD 18.1 million as trials finished enrolling.
  • Phase 3 Study 304 in male pattern hair loss met all primary and secondary endpoints, with average hair count gains of 28.6 and 36.4 hairs per square centimeter against 6.6 for placebo.

How a Pre-Revenue Company Built a USD 798.4 Million Cash Pile

Veradermics (NYSE:MANE) filed its Quarterly Report on November 10, 2026. The company is a late clinical-stage developer of VDPHL01, an oral extended-release minoxidil for pattern hair loss, and has no product approved for sale or revenue. Its cash came from equity: an initial public offering at USD 17.00 a share that raised USD 269.1 million net, and a May 2026 follow-on offering at USD 100.00 a share that, with a private placement, brought in about USD 442.5 million net. Cash and equivalents were USD 132.2 million, with USD 666.2 million in marketable securities. Net cash used in Operating Activities was USD 58.6 million for the nine months, against USD 48.0 million a year earlier.

Phase 3 Data in Men and the Female Study Still to Come

In October 2026, the company announced Phase 3 Study 304 results in 536 men. Hair counts rose by an average of 28.6 hairs per square centimeter on the once-daily dose and 36.4 on the twice-daily dose, versus 6.6 for placebo, with p-values below 0.0001 on the co-primary endpoints. The filing reports no treatment-related serious adverse events and no cardiac events of special interest, and lists peripheral edema and hypertrichosis among common side effects in an earlier trial. Enrollment is complete in Study 306 in women, with topline data expected in the first half of 2027. The filing warns that results in men may not predict results in women, and that the FDA may not accept the 505(b)(2) pathway.

Pre-Launch Spending Lifts General and Administrative Costs

General and administrative expense rose USD 10.5 million in the quarter, which the filing attributes to USD 4.8 million of higher personnel costs, including USD 3.1 million of stock-based compensation, USD 2.7 million of pre-commercial preparation for a possible launch, and USD 2.5 million of public company costs. Research and development fell USD 2.0 million as clinical trial expenses declined, partly offset by Manufacturing and medical education costs. Other income was USD 7.8 million, mostly interest. The per-share comparison is distorted, because the prior-year loss of USD 30.15 a share was spread over about 748,000 common shares, before the IPO. Stockholders' Equity was USD 796.5 million.

Where Things Stand

The company holds USD 798.4 million because it raised equity at scale after positive late-stage data, not because of operating income. Veradermics (NYSE:MANE) lost USD 21.0 million in the quarter, and management expects the cash to last into 2030, though it flags the estimate could be wrong. The next test is the female Phase 3 readout in the first half of 2027, then regulatory review, with no approved product, no sales infrastructure and a cash-pay strategy that may limit sales. The filing gives no guidance beyond the runway and no share price reaction. Watch spending as pre-launch costs build, the Study 306 results and the FDA pathway.